Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Research Base: University of Rochester NCORP Research Base
NCT ID: NCT03367572
NCI Protocol Number: URCC-16070
Status: Recruiting
For more information see ClinicalTrials.gov
Interventions
- Dexamethasone
- Laboratory Biomarker Analysis
- Netupitant/Palonosetron Hydrochloride
- Olanzapine
- Placebo
- Prochlorperazine
- Quality-of-Life Assessment
Condition
Breast Carcinoma
Trial Type
Supportive Care/Symptom Management/PROs
See a list of participating sites on ClinicalTrials.gov